#Israel #Tel Aviv #Galmed Pharmaceuticals #Aramchol #Liver Diseases

Galmed Pharmaceuticals Annual Report 2025

Tel Aviv, Israel - March 31, 2026
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a pioneering entity in the clinical biopharmaceutical sector, has officially filed its Annual Report on Form 20-F for the fiscal year that concluded on December 31, 2025. This significant report has been submitted to the U.S. Securities and Exchange Commission (SEC) and is accessible via their website and Galmed's Investor Relations portal, enhancing transparency and stakeholder engagement.

The 20-F report encapsulates pivotal information regarding Galmed's operational progress, particularly its flagship drug, Aramchol, which is targeted at addressing critical liver disorders such as Non-Alcoholic Steatohepatitis (NASH) and fibrosis. NASH, a growing concern linked to obesity and metabolic syndrome, has been an area of active research and investment for the company, where they aim to innovate and deliver effective treatment solutions.

In the report, Galmed reaffirmed its commitment to advancing Aramchol not just for liver diseases but also for certain oncological applications, thereby broadening its impact across various therapeutic areas. The company is strategically working on expanding its portfolio with a keen eye on developing therapeutic solutions that mesh seamlessly with its existing capabilities.

One highlight of this year's report is the emphasis on the integrated approach towards combination therapies, showcasing the potential synergistic effects of Aramchol when used alongside other established treatments like Stivarga® and Metformin. This exploration of combination therapies could redefine treatment paradigms in addressing complex conditions associated with metabolic disorders.

Focus on Future Developments

Galmed Pharmaceuticals is not resting on its laurels. The company continues to explore innovative strategies to expand its product pipeline, particularly in cardiometabolic diseases. The goal is not merely to treat but to holistically approach the management of these conditions. By leveraging its expertise in drug development, Galmed aims to roll out novel therapeutic candidates that are not only effective but also align with modern healthcare demands.

The report also details anticipated activities, including the timing and execution of clinical trials that are essential for testing new formulations and product candidates. While such initiatives promise to create substantial value for investors, they are accompanied by inherent risks common in the biopharmaceutical landscape.

Moreover, Galmed is cognizant of the myriad challenges that accompany drug development, including regulatory hurdles and market dynamics. The management outlined strategies for managing these uncertainties, which encompass a robust pipeline management, compliance with regulatory expectations, and proactive outreach to potential market partners.

Accessibility of Report

Shareholders and interested parties can easily obtain copies of the Annual Report at no additional cost by reaching out to Galmed's Investor Relations Department. This offers transparency and reinforces Galmed's pledge to maintain strong communication with its stakeholders.

In summary, Galmed Pharmaceuticals' Annual Report for 2025 serves as a comprehensive document that not only outlines the company’s achievements and future pathways but also reinforces their dedication to innovating healthcare solutions. With Aramchol at its forefront, the company is poised to make significant strides in combating liver diseases and improving the quality of life for patients worldwide, making the release of this report a notable milestone in their ongoing narrative of growth and influence within the biopharmaceutical industry.

For more detailed insights, the report is available at SEC's website and Galmed's Investor Relations page.